Association of Epstein-Barr Virus Antibody Levels with Precancerous Gastric Lesions in a High Risk Cohort

Charles S. Rabkin,Wei‐Cheng You,Evelyne T. Lennette,Mitchell H. Gail,Aaron J. Schetter
IF: 11.2
2007-01-01
Cancer Research
Abstract:AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA 1748 The ubiquitous Epstein Barr virus (EBV) has been implicated in a variety of cancers and increasing evidence supports a role in gastric cancer. Viral DNA is detectable in 5-15% of gastric tumors from different geographic regions and EBV antibody titers increase prior to diagnosis of EBV-positive tumors. This study evaluated the association between EBV antibody titers and the precancerous gastric lesions: chronic atrophic gastritis (CAG), intestinal metaplasia (IM) and dysplasia (DYS). Sera were obtained 3 years after diagnosis of either CAG (n=71) or DYS (n=112) in a cohort study from Linqu, China. Immunoglubulin G antibody titers to EBV nuclear antigen (EBNA) and viral capsid antigen (VCA) were determined by 2-fold serial dilutions using immunofluorescence assays. Histologic progression and regression were assessed by gastroscopic examinations at the time of phlebotomy and at follow-up 2 years later. Odds ratios (OR) for greater than median antibody titers were age- and sex-adjusted by multivariable logistic regression. 19/71 (27%) CAG subjects had worse histology and 64/112 (57%) DYS subjects had improved histology on the first examination; 37 subjects progressed and 34 subjects regressed between the two examinations. Subjects with new or persistent DYS tended to have high (>1:320) anti-EBNA titers, particularly at the 2 year follow-up, with OR 3.3 (p trend not significant) and 4.2 (p trend=.05), respectively. Subjects with histologic progression between examinations tended to have both high anti-EBNA and high (>1:640) anti-VCA titers, particularly among those with IM at phlebotomy, with OR 5.7 (p=.01) and 3.8 (p=.05), respectively. Subjects who regressed between examinations were non-signficantly less likely to have high anti-EBNA and anti-VCA titers. These observations are consistent with a role for EBV reactivation at an early phase of gastric carcinogenesis. Future studies incorporating viral DNA detection could potentially reveal stronger associations with a subset of precancerous gastric lesions, as previously found with EBV-positive gastric cancer.
What problem does this paper attempt to address?